We do, however, highlight the need for further studies, including RCTs with less restrictive eligibility criteria, to determine whether InSTI increase the risk and/or severity of paradoxical TB-IRIS in high-risk patients (CD4 counts <50 cells/mm3 and starting ART within four weeks of antituberculosis treatment). Here, CD4 is linked to tuberculosis.